Phase 3 Obesity Trial, Recruiting NCT06379113 Sponsor: Xiaojun Chen Condition: Obesity
Back to Obesity

Phase 3 Obesity Trial, Recruiting

NCT06379113
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a specific, early-stage type of uterine cancer (well-differentiated endometrial cancer, Grade 1) confirmed by a procedure called a hysteroscopy, with no growth into the uterine wall.
  • People with a body mass index (BMI) of 30 or higher (classified as obese).
  • People whose scans (MRI, CT, or ultrasound) show no signs that the cancer has spread outside the uterus.
  • People who are currently being treated with a hormone therapy called progestin as their first treatment — this includes specific medications (megestrol acetate or medroxyprogesterone acetate) and/or a hormonal IUD (intrauterine device).
  • People whose cancer has not responded well enough to progestin treatment — either the cancer stayed the same after 7 months of treatment, or it had not fully cleared after 10 months of treatment.
  • People who wish to preserve their ability to have children or to keep their uterus.
  • People who are able and willing to attend follow-up appointments and stick to the treatment plan.

Who may not be able to join:

  • People who have serious medical conditions or severely reduced liver or kidney function.
  • People whose cancer has been found to have grown into the uterine wall or spread to other parts of the body.
  • People diagnosed with a different type of uterine cancer or another cancer of the reproductive system.
  • People who have breast cancer or another type of cancer or condition that is affected by hormones, where the trial medications (GnRHa or Letrozole) would not be safe to use.
  • People who strongly prefer to have their uterus surgically removed or to pursue a different type of treatment.
  • People who are known or suspected to be pregnant.
  • People who have had a stroke, heart attack, or blood clots, or who are currently experiencing a serious sudden illness of this kind.
  • People who smoke more than 15 cigarettes per day.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 8602133189900

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Xiaojun Chen
Registry
ClinicalTrials.gov
Start date
13 July 2022
Est. completion
30 March 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Complete response rates within 28 weeks of treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov